ClinicalTrials.gg
RecruitingNCT07558681PROPHTAZUpdated Oct 2, 2026

Perioperative Pharmacokinetic/Pharmacodynamic Target Attainment of Piperacillin During Major Hepatic and Pancreatic Surgery

An observational study in Antibiotic Prophylaxis, Pancreatic Surgey and Hepatic Surgery, sponsored by Central Hospital, Nancy, France. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Central Hospital, Nancy, France · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 2, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Surgical Wound Infection with a site in France — 4 open to participants now, 4 under way, 1 of them phase 3. Surgical Wound Infection · France.

Started
2026
with 1 other
Observational
8 of 21
1 open now
Registered
19th of 21
by date
Lead sponsor
3 of 21
Central Hospital, Nancy, France

Among the 21 studies in Surgical Wound Infection with a site in France, this one is one of 2 that started in 2026, is one of 8 observational ones, and was the 19th registered.

Surgical Wound Infection

747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.

Browse Surgical Wound Infection studies →

Open to participants now

4 of the 21 studies in Surgical Wound Infection with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Surgical Wound Infection with a site in France, or all of them as a file.
02

Study summary

Hepatic and pancreatic surgeries are associated with a high risk of surgical site infections, particularly in patients with preoperative biliary drainage, which is frequently associated with bacterial colonization of bile. In this context, perioperative antibiotic prophylaxis is essential, and recent guidelines recommend the use of piperacillin/tazobactam in selected high-risk patients.

However, piperacillin, like other β-lactam antibiotics, exhibits pharmacokinetic variability that may be exacerbated during major surgery due to factors such as fluid shifts, hypoalbuminemia, and changes in volume of distribution. These alterations may result in suboptimal antibiotic exposure during the perioperative period, potentially compromising prophylactic efficacy.

Despite these concerns, standard dosing regimens remain unchanged across different types of major abdominal surgery, including hepatic and pancreatic procedures, which differ significantly in terms of duration, physiological impact, and intraoperative management.

The PROPHTAZ study is a prospective, single-center observational pharmacokinetic study designed to evaluate whether standard perioperative administration of piperacillin/tazobactam achieves predefined pharmacokinetic/pharmacodynamic (PK/PD) targets in patients undergoing hepatic or pancreatic surgery. The primary objective is to determine the proportion of patients achieving adequate PK/PD exposure during surgery. Secondary objectives include describing perioperative plasma concentrations, assessing pharmacokinetic variability, identifying factors associated with target non-attainment, and comparing outcomes between surgical subgroups.

This study aims to provide clinically relevant data to assess the adequacy of current prophylactic dosing strategies and to support potential optimization of antibiotic administration in high-risk surgical patients.

03

Conditions studied

  • Antibiotic Prophylaxis
  • Pancreatic Surgey
  • Hepatic Surgery

Keywords

  • PK/PD target atttainment
  • piperacillin
  • surgical site infection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients undergoing elective hepatic or pancreatic surgery at a tertiary care university hospital (CHRU Nancy, France). Eligible patients are those receiving perioperative antibiotic prophylaxis with piperacillin/tazobactam according to current clinical guidelines, particularly in the context of preoperative biliary drainage or high risk of biliary contamination.

These patients represent a high-risk surgical population for surgical site infections, characterized by complex procedures, potential intraoperative hemodynamic variations, and significant pharmacokinetic variability. Patients are managed in a perioperative setting including the operating room and postoperative admission to a surgical intensive care or intermediate care unit.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults > or = to 18 years old
  • Scheduled for major hepatic or pancreatic surgery
  • Receiving piperacillin/tazobactam as perioperative antibiotic prophylaxis according to guidelines

Exclusion criteria

Exclusion Criteria:

  • decline to participate
  • Known allergy of beta-lactam
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adult patients with scheduled pancreatic or major hepatic surgery

    Adult patients with scheduled pancreatic surgery or major hepatic receiving piperacillin/tazobactam as antibiotic prophylaxis

06

What researchers measure

Primary outcomes

  1. PK/PD target attainment of piperacillin

    Proportion of patients achieving the predefined\* PK/PD target during the perioperative period \*estimated free concentration of piperacillin (80% of the total concentration) above the MIC of the isolated pathogen from bile samples throughout the surgical procedure (from incision to wound closure)

    Time frame: 4 hours after the administration of piperacillin

Secondary outcomes

  1. Plasma piperacillin concentration

    Total (measured) et free (estimated) concentration of piperacilline throughout at two timepoints: surgical incision and wound closure

    Time frame: 4 hours after the administration of piperacillin

  2. Factors associated with target attainment

    Analysis of clinical and biological covariates associated with pharmacokinetic variability and the achievement of pharmacodynamic targets

    Time frame: 4 hours after the administration of piperacillin

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jan 2027, 3 months after the start.

Of 65 non-industry observational studies under Surgical Wound Infection, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 53. This study's planned 3 months is below that.

Counting every sponsor, half of 68 studies reached it within 21 months; a quarter within 9 and three quarters within 53.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: start May 2026 → Sep 2026 and primary completion Mar 2027 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
Apr 30, 2026
StartActual
Sep 25, 2026was May 2026
Primary completionEst.
Jan 1, 2027was Mar 2027
CompletionEst.
May 1, 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 2, 2026
Sites
1 site added. CHRU de Nancy is now Not yet recruiting
Show site
  • CHRU de NANCY · Nancy, France
Oct 2, 2026
Start date
May 1, 2026→Sep 25, 2026 (actual)
Oct 2, 2026
Primary completion
Mar 1, 2027→Jan 1, 2027
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Not yet recruiting→Recruiting
    1 site added. CHRU de Nancy is now Not yet recruiting
    Show site
    • CHRU de NANCY · Nancy, France
    Start date May 1, 2026→Sep 25, 2026 (now actual)
    Primary completion Mar 1, 2027→Jan 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07558681
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
Sep 25, 2026
Primary completion
Jan 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Oct 2, 2026

Study contacts

Emmanuel NOVY, MD, PhD
Contact
e.novy@chru-nancy.fr
+33 383157437

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion